Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | HPGD | P15428 | 2/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.84 |
| ▸ | POLB | P06746 | 1/20 | 0.84 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.84 |
| ▸ | NQO2 | P16083 | 3/20 | 0.78 |
| ▸ | MTNR1A | P48039 | 17/20 | 0.76 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428037 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL15428075 | 0.91 | KDM4E (0.81) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL6950433 | 0.91 | ALDH1A1 (0.70) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL15427782 | 0.90 | KDM4E (0.79) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL15427770 | 0.89 | KDM4E (0.78) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL15428004 | 0.88 | NQO2 (1.00) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL31543713 | 0.86 | MTNR1A (1.00) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL31530479 | 0.86 | MTNR1A (0.78) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL8946916 | 0.86 | MTNR1A (1.00) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL31530480 | 0.86 | MTNR1A (0.78) | KDM4EALDH1A1HPGDHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007101863-A1 | THERAPEUTIC COMBINATION OF A 5HT2 RECEPTOR ANTAGONIST AND OF A 5HT2 RECEPTOR ACTIVATOR | MACEF (FR) | 2007-09-13 | — | — | WO | claimed |
| EP-0851855-B9 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | MACEF (FR) | 2003-05-21 | — | — | EP | claimed |
| EP-0851855-B1 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | MACEF (FR) | 2002-06-05 | — | — | EP | claimed |
| EP-2873660-B1 | INDOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-9376449-B2 | Indole carboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20150203505-A1 | INDOLE CARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-2873660-A1 | INDOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014010602-A1 | INDOLECARBOXAMIDE DERIVATIVE | アステラス製薬株式会社 (JP) | 2014-01-16 | — | — | WO | disclosed |
| US-8258173-B2 | Melatonin derivatives and their use as antioxidants | UNIVERSITY OF SUNDERLAND (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20100063125-A1 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | UNIVERSITY OF SUNDERLAND (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-2083818-A2 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | University of Sunderland (GB) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008062167-A2 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | UNIVERSITY OF SUNDERLAND (GB) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007101863-A1 | THERAPEUTIC COMBINATION OF A 5HT2 RECEPTOR ANTAGONIST AND OF A 5HT2 RECEPTOR ACTIVATOR | MACEF (FR) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007101863-A1 | THERAPEUTIC COMBINATION OF A 5HT2 RECEPTOR ANTAGONIST AND OF A 5HT2 RECEPTOR ACTIVATOR | MACEF (FR) | 2007-09-13 | — | — | WO | disclosed |
| EP-0851855-B9 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | MACEF (FR) | 2003-05-21 | — | — | EP | disclosed |
| EP-0851855-B1 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | MACEF (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-6140372-A | N-(2-(2-ACETYL-7-METHOXYNAPHTH-1-YL)ETHYL)ACETAMIDE; SEDATIVES; MELATONIN DISORDERS; DRUGS; COSMETICS; ANTIDEPRESSANTS; PSYCHIATRIC DISORDERS, E.G., STRESS, ANXIOLYTIC AGENTS, INSOMNIA, SCHIZOPHRENIA, PSYCHOSIS | CEMAF AND LABORATORIES BESINS ISOVESCO S.A. (FR) | 2000-10-31 | — | — | US | disclosed |
| US-6004991-A | COMPOUNDS FOR COSMETICS WITH ENANTIOMORPHS | CEMAF AND LABORATOIRES BESINS ISCOVESCO S.A. (FR) | 1999-12-21 | — | — | US | disclosed |
| EP-0851855-A1 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | CEMAF (FR) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997006140-A1 | ACYLATED DERIVATIVES OF MELATONIN AND ITS ANALOGUES, USEFUL AS MEDICAMENTS | CEMAF (FR) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063125-A1 | MELATONIN DERIVATIVES AND THEIR USE AS ANTIOXIDANTS | MTNR1A, MTNR1B, TXNRD2 | KDM4E 2064/4885ALDH1A1 250/4885HPGD 320/4885 |
| US-20150203505-A1 | INDOLE CARBOXAMIDE DERIVATIVE | MTNR1A, MTNR1B, IDO2 | KDM4E 1577/4885ALDH1A1 383/4885HPGD 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.